Niven Mehra, MD, PhD, is Consultant in Medical Oncology at the Radboud University Medical Centre (Radboudumc) in Nijmegen, the Netherlands, a post he has held since 2016. Dr Mehra graduated with an MD from the University Medical Centre Utrecht in the Netherlands in 2002. He completed a PhD in translational cancer research on non‐invasive prognostic and predictive biomarkers in 2006, followed by training in internal medicine from 2006 to 2011 and in medical oncology from 2011 to 2014. He then focused on urogenital oncology during a clinical research fellowship at the Royal Marsden NHS Trust and the Institute of Cancer Research (ICR) in London, UK, studying under Johann de Bono, where he was a sub‐investigator for clinical trials in the prostate targeted therapy group.
Dr Mehra’s post‐doctorate research at the ICR focused on biomarker discovery in liquid biopsies and on the role of immune suppressive cells in prostate cancer. He now specializes in genitourinary (GU) cancer, particularly metastatic prostate cancer and advanced urothelial cancer, and his research group focuses on personalized cancer therapy for GU cancers, through in‐depth assessment of tumour biopsies and circulating cell‐free DNA, and through predictive immunological biomarkers. He chairs the Molecular Tumour Board at the Radboudumc and the prostate cancer working group of the Dutch Uro‐Oncology Study (DUOS) group in the Netherlands, and was one of the initiators of ProBCI, a prospective Dutch bladder cancer infrastructure and registry.
He is a member of the educational publications working group of the European Society for Medical Oncology (ESMO), and the author of peer‐reviewed research papers in numerous international journals and of cancer textbooks and handbooks.